ArticleMolecular therapy : the journal of the American Society of Gene Therapy2020
Perivascular Stem Cell-Derived Cyclophilin A Improves Uterine Environment with Asherman's Syndrome via HIF1α-Dependent Angiogenesis.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Evolution of biotechnological advances and regenerative therapies for endometrial disorders: a systematic review.Human reproduction update · 2024Pooled it
- Co-delivery of endometrial mesenchymal stem cells and macrophages by an electrospun patch promotes angiogenesis during endometrial injury repair via VEGF related signalling.Stem cell research & therapy · 2026Article
- Article
- Novel injectable sodium alginate hydrogel developed for improved endometrial repair with human umbilical cord mesenchymal stem cells.Drug delivery and translational research · 2025Article
- Quantum dots as biocompatible small RNA nanocarriers modulating macrophage polarization to treat Asherman's syndrome.NPJ Regenerative medicine · 2025Article
- Macrophages: a double-edged sword in female reproduction and disorders.Experimental & molecular medicine · 2025Review
- Rodent models of functional hypothalamic amenorrhea: a systematic scoping review.Frontiers in endocrinology · 2025Article
- Hypoxia and the endometrium: An indispensable role for HIF-1α as therapeutic strategies.Redox biology · 2024Review
- Endometrial Stem Cells: Orchestrating Dynamic Regeneration of Endometrium and Their Implications in Diverse Endometrial Disorders.International journal of biological sciences · 2024Review
- Endometrial organoids: a reservoir of functional mitochondria for uterine repair.Theranostics · 2024Article
- CFP1 governs uterine epigenetic landscapes to intervene in progesterone responses for uterine physiology and suppression of endometriosis.Nature communications · 2023Article
- Article
- Liposome-mediated small RNA delivery to convert the macrophage polarity: A novel therapeutic approach to treat inflammatory uterine disease.Molecular therapy. Nucleic acids · 2022Article
- Research progress of stem cell therapy for endometrial injury.Materials today. Bio · 2022Review
- Article
- Treating intrauterine adhesion using conditionally reprogrammed physiological endometrial epithelial cells.Stem cell research & therapy · 2022Article
- The Top 100 Most Cited Articles on Intrauterine Adhesion: a Bibliometric Analysis.Reproductive sciences (Thousand Oaks, Calif.) · 2022Article
- Generation of macrophage containing alveolar organoids derived from human pluripotent stem cells for pulmonary fibrosis modeling and drug efficacy testing.Cell & bioscience · 2021Article
- Article
- Endometrial Perivascular Progenitor Cells and Uterus Regeneration.Journal of personalized medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asherman's syndrome (AS) is characterized by intrauterine adhesions or fibrosis resulting from scarring inside the endometrium. AS is associated with infertility, recurrent miscarriage, and placental abnormalities. Although mesenchymal stem cells show therapeutic promise for the treatment of AS, the molecular mechanisms underlying its pathophysiology remain unclear. We ascertained that mice with AS, like human patients with AS, suffer from extensive fibrosis, oligo/amenorrhea, and infertility. Human perivascular stem cells (hPVSCs) from umbilical cords repaired uterine damage in mice with AS, regardless of their delivery routes. In mice with AS, embryo implantation is aberrantly deferred, which leads to intrauterine growth restriction followed by no delivery at term. hPVSC administration significantly improved implantation defects and subsequent poor pregnancy outcomes via hypoxia inducible factor 1α (HIF1α)-dependent angiogenesis in a dose-dependent manner. Pharmacologic inhibition of HIF1α activity hindered hPVSC actions on pregnancy outcomes, whereas stabilization of HIF1α activity facilitated such actions. Furthermore, therapeutic effects of hPVSCs were not observed in uterine-specific HIF1α-knockout mice with AS. Secretome analyses of hPVSCs identified cyclophilin-A as the major paracrine factor for hPVSC therapy via HIF1α-dependent angiogenesis. Collectively, we demonstrate that hPVSCs-derived cyclophilin-A facilitates HIF1α-dependent angiogenesis to ameliorate compromised uterine environments in mice with AS, representing the major pathophysiologic features of humans with AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.